Lancet calls for big jump in global cigarette tax

	Tweet

Governments around the world should increase taxation on cigarettes by 50 percent a year to combat booming lung cancer rates, The Lancet medical journal said on Friday.

An editorial said lung cancer, of which smoking accounts for 90 percent of cases, has become the most common and most deadly cancer and drastic action was needed.

“We urge all governments to commit to annual price increases of 50 percent,” the authoritative journal said, judging it the only way to deal with the “endemic tragedy” which kills 5 million people a year.

While health campaigns have helped curb Smoking levels in Britain and North America, the trend to smoke has grown in developing nations.

“Within 20 years, 75 percent of people dying of cancer will be in the developing world - where ever-expanding markets for eager new smokers ensure that lung cancer climbs up the big-killers lists,” it said.

The Lancet said that if the cause of lung cancer were an infections agent, millions if not billions of dollars would have been poured into an eradication campaign.

A worrying sign has been tobacco manufacturers targeting new markets in Asia to compensate for static or declining sales in the developed world, it said.

The Lancet said the World Bank estimates a price increase of 10 percent would reduce demand for tobacco products by 4 percent in high income countries and 8 percent in low and middle income nations.

“Tobacco manufacturers continue ruthlessly to promote a pastime that will kill 50 percent of those who acquire the habit. The least we should do it match this 50 percent mortality with a 50 percent tax.”

RELATED STORIES:
Smokers’ lung cancer risk identified in CT screening study   Symptoms often felt long before lung cancer found   Study finds evidence of increased lung cancer risk among tuberculosis patients   Study finds genetic link to lung cancer   Lung Cancer Linked To Gulf War Fires   Targeted cancer drug fails to help patients - study   Genes affect smoking behavior, lung cancer risk   FDA clears Genentech’s Tarceva for lung cancer   Genentech drug slows progression of lung cancer   Red wine may protect against lung cancer   Lung cancer linked to risk of stroke   False-positive cancer screening results costly

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]